FOSTER CITY, California, e SHANGHAI--(BUSINESS WIRE)--Terns Pharmaceuticals, Inc., multinazionale biofarmaceutica dedita alla scoperta e allo sviluppo di terapie innovative per il trattamento della steatosi epatica non alcolica (non-alcoholic steatohepatitis, NASH) e del cancro, ha annunciato oggi che TERN-101, agonista sperimentale del recettore farnesoide X (farnesoid X receptor, FXR), ha ottenuto dall’ente statunitense preposto al controllo dei farmaci e degli alimenti (Food and Drug Adminis
15:15
MENLO PARK, Calif.--(BUSINESS WIRE)-- #RAPID--iSchemaView/RAPID, the worldwide leader in advanced imaging for stroke has new global findings based on compelling data from over 400,000 scans.
15:00
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the Pediatric Committee (PDCO) of the European Medicines Agency (EMA) has issued a positive opinion for the company’s pediatric investigation plan (PIP) for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). Narsoplimab, also referred to as OMS721, is Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2
15:00
NEW YORK & FREIBURG, Germany--(BUSINESS WIRE)--Gotham Therapeutics and ProQinase establish an array of advanced biochemical and cellular assays to characterize epitranscriptomic-directed compounds.
15:00
OVERLAND PARK, Kan.--(BUSINESS WIRE)--Netsmart and Adirondack Health Institute (AHI) announced today their recent partnership to improve care coordination across 23 participating healthcare organizations as part of the New York Health Homes initiative. For more than a decade, the powerful Netsmart network has enabled Netsmart clients, including a variety of New York Health Homes, to easily share and exchange data with health information exchanges and providers across the healthcare continuum. T
15:00
FAIRFAX, Va.--(BUSINESS WIRE)-- #AmericanCollegeRheumatology--Vizuri Health Sciences will present clinical study results at the American College of Rheumatology Annual Meeting in Atlanta on November 12, 2019.
13:58
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. to Announce Third Quarter 2019 Results and Host a Conference Call and Webcast on November 8, 2019
13:05
PLEASANTON, Calif.--(BUSINESS WIRE)-- #CROs--CROs are making significant progress in advancing the industrywide move to improve clinical trial performance, according to one of the largest surveys
13:03
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #earnings--Incyte Reports 2019 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
13:00
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation to present at Dawson James Securities 5th Annual Small Cap Growth Conference.
13:00
KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Third-Quarter 2019 Financial Results
12:45
The UK-based pharma company said that it has started dosing of patients in the phase 3 programme, which will test gepotidacin in two studies – EAGLE-1 and EAGLE-2. The post GSK launches phase 3 programme for gepotidacin in uUTI and GC appeared first on Pharmaceutical Business review.
12:35
Bavencio, which is a human anti-programmed death ligand-1 (PD-L1) antibody, has been demonstrated in preclinical models to engage both the adaptive and innate immune functions. The combined therapy The post EC approves Pfizer’s Bavencio plus axitinib to treat advanced RCC appeared first on Pharmaceutical Business review.
12:35
“We are excited about the opportunity to partner with Glympse Bio to help inform our NASH development program,” said Mani Subramanian, MD, PhD Senior Vice President, Liver Diseases, The post Gilead and Glympse Bio announce strategic collaboration for use of biomarker technology in NASH clinical development appeared first on Pharmaceutical Business review.
12:35
VIENNA, Austria & OSLO, Norway--(BUSINESS WIRE)--Themis Bioscience and CEPI – the Coalition for Epidemic Preparedness Innovations – announced today the first administration to healthy volunteers in a Phase 1 clinical trial with Themis’ vaccine candidate against Lassa fever. The MV-LASV Lassa fever vaccine candidate, is based on Themis’ proprietary measles vector platform and exclusively-licensed discoveries made at Institut Pasteur. The MV-LASV Lassa fever vaccine program is funded through a...
12:00
The trial met a primary endpoint by showing a statistically significant and clinically meaningful improvement in the final PFS analysis in patients treated with the combination of Imfinzi The post Imfinzi and Imfinzi plus tremelimumab delayed disease progression in POSEIDON trial appeared first on Pharmaceutical Business review.
11:36
HOUSTON--(BUSINESS WIRE)--Vapogenix Reports Encouraging Phase II Results of Topical Non-Opioid Pain Medication
11:30
FOSTER CITY, Calif. & SHANGHAI--(BUSINESS WIRE)--Terns Pharmaceuticals Receives Fast Track Designation from the FDA for TERN-101, an FXR Agonist for the Treatment of NASH
11:00
美国加州福斯特城与中国上海--(BUSINESS WIRE)--(美国商业资讯)--Terns Pharmaceuticals 拓臻生物一家专注非酒精性脂肪性肝炎（NASH）和癌症创新疗法研发的全球生物制药公司，今天宣布其候选药物法尼醇X受体（FXR）激动剂TERN-101已获得美国食品和药物管理局（FDA）针对治疗NASH适应症的快速通道认证。 拓臻生物首席医学官Erin Quirk博士表示：“我们非常高兴看到美国FDA对TERN-101在用于目前尚无有效治疗选择,存在未满足临床需求的NASH患者中治疗潜力的认可。获得快速通道认证是尽快将这种有潜力的治疗方法应用于NASH患者的一个重要步骤，我们希望在推进TERN-101的临床开发过程中与FDA紧密合作以加速其进程。” 到目前为止，在Ⅰ期临床研究中，TERN-101显示了与每日一次给药一致的临床药代动力学特性。在维也纳举行的2019年国际肝病大会上，拓臻生物发表了TERN-101的临床前研究数据，证明TERN-101在NASH临床前动物模型中降低了肝脏脂肪变性、炎症、气球样变和纤维化。 TERN-101和TERN-201（氨基脲敏感
11:00
Bergen, Norway 22nd October 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, today announces that the U.S. Food and Drug...
Tue Oct 22, 2019 08:10
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced results of a post-hoc analysis of data from the Phase 3 HOPE (Hemoglobin Oxygen Affinity...
Mon Oct 21, 2019 08:10
FOSTER CITY, Calif.--(BUSINESS WIRE)--Oct. 28, 2019-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today...
Mon Oct 28, 2019 06:10
London, UK 28 October 2019 -- GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that patient dosing has begun in a phase III clinical programme investigating gepotidacin, the first in a new chemical class of antibiotics called triazaacenaphthylene...
Mon Oct 28, 2019 06:10
EDINBURGH, United Kingdom, Oct. 25, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for its Phase III study (NuTide:121) of the...
Fri Oct 25, 2019 07:10
Seeking healthy volunteers age 65+ Respiratory Syncytial Virus, or RSV, is a common virus but much more than a cold. It can be serious for babies and older adults with health conditions. Researchers are testing investigational vaccines that may protect against RSV and they need healthy volunteers age 65+. Not available from your regular doctor. Research studies are an important part of developing potential future treatment options. Without them, progress in medicine would not be possible. Right...
Mon Oct 28, 2019 00:00
Seeking healthy volunteers age 65+ Respiratory Syncytial Virus, or RSV, is a common virus but much more than a cold. It can be serious for babies and older adults with health conditions. Researchers are testing investigational vaccines that may protect against RSV and they need healthy volunteers age 65+. Not available from your regular doctor. Research studies are an important part of developing potential future treatment options. Without them, progress in medicine would not be possible. Right...
Mon Oct 28, 2019 00:00
Seeking healthy volunteers age 65+ Respiratory Syncytial Virus, or RSV, is a common virus but much more than a cold. It can be serious for babies and older adults with health conditions. Researchers are testing investigational vaccines that may protect against RSV and they need healthy volunteers age 65+. Not available from your regular doctor. Research studies are an important part of developing potential future treatment options. Without them, progress in medicine would not be possible. Right...
Mon Oct 28, 2019 00:00
Seeking healthy volunteers age 65+ Respiratory Syncytial Virus, or RSV, is a common virus but much more than a cold. It can be serious for babies and older adults with health conditions. Researchers are testing investigational vaccines that may protect against RSV and they need healthy volunteers age 65+. Not available from your regular doctor. Research studies are an important part of developing potential future treatment options. Without them, progress in medicine would not be possible. Right...
Mon Oct 28, 2019 00:00
Seeking healthy volunteers age 65+ Respiratory Syncytial Virus, or RSV, is a common virus but much more than a cold. It can be serious for babies and older adults with health conditions. Researchers are testing investigational vaccines that may protect against RSV and they need healthy volunteers age 65+. Not available from your regular doctor. Research studies are an important part of developing potential future treatment options. Without them, progress in medicine would not be possible. Right...
Mon Oct 28, 2019 00:00
Seeking healthy volunteers age 65+ Respiratory Syncytial Virus, or RSV, is a common virus but much more than a cold. It can be serious for babies and older adults with health conditions. Researchers are testing investigational vaccines that may protect against RSV and they need healthy volunteers age 65+. Not available from your regular doctor. Research studies are an important part of developing potential future treatment options. Without them, progress in medicine would not be possible. Right...
Mon Oct 28, 2019 00:00
Seeking healthy volunteers age 65+ Respiratory Syncytial Virus, or RSV, is a common virus but much more than a cold. It can be serious for babies and older adults with health conditions. Researchers are testing investigational vaccines that may protect against RSV and they need healthy volunteers age 65+. Not available from your regular doctor. Research studies are an important part of developing potential future treatment options. Without them, progress in medicine would not be possible. Right...
Mon Oct 28, 2019 00:00
Seeking healthy volunteers age 65+ Respiratory Syncytial Virus, or RSV, is a common virus but much more than a cold. It can be serious for babies and older adults with health conditions. Researchers are testing investigational vaccines that may protect against RSV and they need healthy volunteers age 65+. Not available from your regular doctor. Research studies are an important part of developing potential future treatment options. Without them, progress in medicine would not be possible. Right...
Mon Oct 28, 2019 00:00
Seeking healthy volunteers age 65+ Respiratory Syncytial Virus, or RSV, is a common virus but much more than a cold. It can be serious for babies and older adults with health conditions. Researchers are testing investigational vaccines that may protect against RSV and they need healthy volunteers age 65+. Not available from your regular doctor. Research studies are an important part of developing potential future treatment options. Without them, progress in medicine would not be possible. Right...
Mon Oct 28, 2019 00:00
Seeking healthy volunteers age 65+ Respiratory Syncytial Virus, or RSV, is a common virus but much more than a cold. It can be serious for babies and older adults with health conditions. Researchers are testing investigational vaccines that may protect against RSV and they need healthy volunteers age 65+. Not available from your regular doctor. Research studies are an important part of developing potential future treatment options. Without them, progress in medicine would not be possible. Right...
Mon Oct 28, 2019 00:00
Seeking healthy volunteers age 65+ Respiratory Syncytial Virus, or RSV, is a common virus but much more than a cold. It can be serious for babies and older adults with health conditions. Researchers are testing investigational vaccines that may protect against RSV and they need healthy volunteers age 65+. Not available from your regular doctor. Research studies are an important part of developing potential future treatment options. Without them, progress in medicine would not be possible. Right...
Mon Oct 28, 2019 00:00
Seeking healthy volunteers age 65+ Respiratory Syncytial Virus, or RSV, is a common virus but much more than a cold. It can be serious for babies and older adults with health conditions. Researchers are testing investigational vaccines that may protect against RSV and they need healthy volunteers age 65+. Not available from your regular doctor. Research studies are an important part of developing potential future treatment options. Without them, progress in medicine would not be possible. Right...
Mon Oct 28, 2019 00:00
Seeking healthy volunteers age 65+ Respiratory Syncytial Virus, or RSV, is a common virus but much more than a cold. It can be serious for babies and older adults with health conditions. Researchers are testing investigational vaccines that may protect against RSV and they need healthy volunteers age 65+. Not available from your regular doctor. Research studies are an important part of developing potential future treatment options. Without them, progress in medicine would not be possible. Right...
Mon Oct 28, 2019 00:00
Seeking healthy volunteers age 65+ Respiratory Syncytial Virus, or RSV, is a common virus but much more than a cold. It can be serious for babies and older adults with health conditions. Researchers are testing investigational vaccines that may protect against RSV and they need healthy volunteers age 65+. Not available from your regular doctor. Research studies are an important part of developing potential future treatment options. Without them, progress in medicine would not be possible. Right...
Mon Oct 28, 2019 00:00
Seeking healthy volunteers age 65+ Respiratory Syncytial Virus, or RSV, is a common virus but much more than a cold. It can be serious for babies and older adults with health conditions. Researchers are testing investigational vaccines that may protect against RSV and they need healthy volunteers age 65+. Not available from your regular doctor. Research studies are an important part of developing potential future treatment options. Without them, progress in medicine would not be possible. Right...
Mon Oct 28, 2019 00:00
Seeking healthy volunteers age 65+ Respiratory Syncytial Virus, or RSV, is a common virus but much more than a cold. It can be serious for babies and older adults with health conditions. Researchers are testing investigational vaccines that may protect against RSV and they need healthy volunteers age 65+. Not available from your regular doctor. Research studies are an important part of developing potential future treatment options. Without them, progress in medicine would not be possible. Right...
Mon Oct 28, 2019 00:00
Seeking healthy volunteers age 65+ Respiratory Syncytial Virus, or RSV, is a common virus but much more than a cold. It can be serious for babies and older adults with health conditions. Researchers are testing investigational vaccines that may protect against RSV and they need healthy volunteers age 65+. Not available from your regular doctor. Research studies are an important part of developing potential future treatment options. Without them, progress in medicine would not be possible. Right...
Mon Oct 28, 2019 00:00
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the third quarter ended September 30, 2019. “In the third quarter the business environment remained steady, and cancellations continued at normal levels,” said August J. Troendle, President & Chief Executive Officer. Third Quarter 2019 Financial Results Revenue for the three months ended September 30, 2019 increased 20.6% to $216.2 million, compared to $179.3 million for the
Mon Oct 28, 2019 22:15
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced positive progression-free survival (PFS) results for IMFINZI and tremelimumab, an anti-CTLA-4 antibody, when added to chemotherapy, from the Phase III POSEIDON trial in previously-untreated Stage IV (metastatic) non-small cell lung cancer (NSCLC). The trial met a primary endpoint by showing a statistically significant and clinically meaningful improvement in the final PFS analysis in patients treated with the combination of IMFINZI
Mon Oct 28, 2019 21:14
PORTLAND, Maine--(BUSINESS WIRE)-- #musicitsscience--MedRhythms initiates multi-site randomized controlled trial at the nation’s top rehab hospitals for its post-stroke walking rehabilitation device.
Mon Oct 28, 2019 20:00
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, today presented data from its ongoing Phase 1b/2 clinical study of rebastinib, an oral TIE2 kinase inhibitor, in combination with paclitaxel at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. In addition, the Company also presented data from preclinical studies of DCC-311
Mon Oct 28, 2019 18:30
GUILFORD, Conn.--(BUSINESS WIRE)--BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it intends to complete a
Mon Oct 28, 2019 16:16
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) has submitted the first sections of the rolling submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), a far-too-often deadly complication of stem-cell transplantation. Narsoplimab, also known as “OMS721,” is Omeros’ lead human monoclonal antibody targeting mannan-bindin
Mon Oct 28, 2019 14:45
BOSTON--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announces the first data from its Phase 1 study evaluating novel bispecific antibody ZW25 in combination with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma (GEA) in a poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 26 - 30 in Boston. “Today we report
Mon Oct 28, 2019 14:30
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced the presentation of clinical data for linaclotide and MD-7246, as well as results from a survey for patients with persistent gastroesophageal reflux disease (GERD), from Ironwood and its collaborators during the American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting being held in San Antonio, TX, October 25 through October 30, 2019. A linaclotide poster at
Mon Oct 28, 2019 14:00
“The MAHOGANY study for patients with gastric or gastroesophageal junction cancer is designed to support registration of margetuximab and is a part of our strategy to advance margetuximab The post MacroGenics announces initiation of phase 2/3 MAHOGANY study of margetuximab in gastric or gastroesophageal junction cancer appeared first on Pharmaceutical Business review.
Mon Oct 28, 2019 13:40
Phase 1 study results showed escalating doses of TBC-1002 to be well tolerated with no dose limiting toxicity and no irritative voiding (cystitis) symptoms. No systemic exposure or The post LIPAC Oncology announces successful completion of phase 1 bladder cancer clinical study and initiation of phase 2A study appeared first on Pharmaceutical Business review.
Mon Oct 28, 2019 13:40
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it will report its third quarter 2019 financial results on Monday, November 4, 2019. In connection with the earnings release, Deciphera’s management team will host a live conference call and webcast at 4:30 PM ET on Monday, November 4, 2019, to discuss the Company’s financial results and pro
Mon Oct 28, 2019 13:00
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle presented data supporting clinical use of the DecisionDx®-Melanoma test to inform decisions of whether to discuss or recommend SLNB.
Mon Oct 28, 2019 13:00
Gilteritinib can be used in the treatment of AML patients whose disease is in the relapsed or refractory stage, and who express a FLT3 mutation (FLT3mut+). The oral The post Astellas’ gilteritinib secures EC approval to treat acute myeloid leukaemia appeared first on Pharmaceutical Business review.
Mon Oct 28, 2019 13:40
NEW YORK--(BUSINESS WIRE)--IVERIC bio, Inc. announced initial topline data confirming that Zimura® met its prespecified primary endpoint in its Phase 2b clinical trial.
Mon Oct 28, 2019 12:30
WASHINGTON--(BUSINESS WIRE)-- #Brexit--On October 23, the Association of Clinical Research Organizations (ACRO) and the Congressional Research & Development Caucus hosted a Congressional Briefing on Capitol Hill about the advancements clinical research and technology companies are making in drug development. The briefing included representatives from ACRO member companies who discussed how they are driving 21st-century innovation in clinical trials through advancements such as real-world data...
Mon Oct 28, 2019 12:00
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου